Butorfanol [INN-Spanish]

Butorfanol [INN-Spanish] Brand names, Butorfanol [INN-Spanish] Analogs

Butorfanol [INN-Spanish] Brand Names Mixture

No information avaliable

Butorfanol [INN-Spanish] Chemical_Formula

C₂₁H₂₉NO₂

Butorfanol [INN-Spanish] RX_link

http://www.rxlist.com/cgi/generic2/butor.htm

Butorfanol [INN-Spanish] fda sheet

Butorfanol_[INN-Spanish] FDA

Butorfanol [INN-Spanish] msds (material safety sheet)

Butorfanol_[INN-Spanish] MSDS

Butorfanol [INN-Spanish] Synthesis Reference

No information avaliable

Butorfanol [INN-Spanish] Molecular Weight

327.461 g/mol

Butorfanol [INN-Spanish] Melting Point

No information avaliable

Butorfanol [INN-Spanish] H₂O Solubility

Moderate

Butorfanol [INN-Spanish] State

Solid

Butorfanol [INN-Spanish] LogP

4.176

Butorfanol [INN-Spanish] Dosage Forms

Drops; Drug premix; Gel; Globules; Liquid; Powder for solution; Solution; Spray; Tablet

Butorfanol [INN-Spanish] Indication

For the management of pain when the use of an opioid analgesic is appropriate. Also indicated as a preoperative or preanesthetic medication, as a supplement to balanced anesthesia, and for the relief of pain during labor.

Butorfanol [INN-Spanish] Pharmacology

Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.

Butorfanol [INN-Spanish] Absorption

Rapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.

Butorfanol [INN-Spanish] side effects and Toxicity

The clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.

Butorfanol [INN-Spanish] Patient Information

Butorfanol [INN-Spanish] Organisms Affected

Humans and other mammals